Education
About Us
Working with TipRanks
Follow Us
Thiogenesis Therapeutics Corp (TSE:TTI)
:TTI
RESEARCH TOOLSreports
TTI Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.50 - C$0.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)27.80K
Market Cap
C$39.40M
Enterprise ValueC$32.42M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Nov 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding51,835,957
10 Day Avg. Volume8,174
30 Day Avg. Volume27,795
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Thiogenesis Therapeutics Corp News
TTI FAQ
What was Thiogenesis Therapeutics Corp’s price range in the past 12 months?
Thiogenesis Therapeutics Corp lowest stock price was C$0.50 and its highest was C$0.88 in the past 12 months.
What is Thiogenesis Therapeutics Corp’s market cap?
Thiogenesis Therapeutics Corp’s market cap is C$39.40M.
When is Thiogenesis Therapeutics Corp’s upcoming earnings report date?
Thiogenesis Therapeutics Corp’s upcoming earnings report date is Nov 25, 2025 which is in 83 days.
How were Thiogenesis Therapeutics Corp’s earnings last quarter?
Thiogenesis Therapeutics Corp released its earnings results on Aug 18, 2025. The company reported -C$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.04.
Is Thiogenesis Therapeutics Corp overvalued?
According to Wall Street analysts Thiogenesis Therapeutics Corp’s price is currently Overvalued.
Does Thiogenesis Therapeutics Corp pay dividends?
Thiogenesis Therapeutics Corp does not currently pay dividends.
What is Thiogenesis Therapeutics Corp’s EPS estimate?
Thiogenesis Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Thiogenesis Therapeutics Corp have?
Thiogenesis Therapeutics Corp has 51,835,957 shares outstanding.
What happened to Thiogenesis Therapeutics Corp’s price movement after its last earnings report?
Thiogenesis Therapeutics Corp reported an EPS of -C$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.25%.
Which hedge fund is a major shareholder of Thiogenesis Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:TTI
Thiogenesis Therapeutics Corp Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth C$48.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.40%
12-Months-Change
Fundamentals
Return on Equity
-195.45%
Trailing 12-Months
Asset Growth
-61.69%
Trailing 12-Months
Company Description
Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is an early stage biotech company. It is developing novel drug formulations that act as precursors to cysteamine, which is a small aminothiol compound that is endogenous in humans in small quantities.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Helix BioPharma
―
PharmaTher Holdings Ltd
―
NurExone Biologic
―
Glow LifeTech
―
Ownership Overview
1.81% Insiders
―
Mutual Funds
― Other Institutional Investors
98.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---